2020
DOI: 10.1111/cas.14566
|View full text |Cite
|
Sign up to set email alerts
|

Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 83 publications
0
2
0
Order By: Relevance
“…According to the statistics of the American Cancer Society in 2020, over 21,000 women were diagnosed with ovarian cancer, of which nearly 14,000 women died from this disease ( Siegel et al, 2020 ). Despite the application of two newly developed molecularly targeted drugs, PARP inhibitors (PARPi) and antiangiogenic agents, ovarian cancer remains the most lethal gynecologic malignancy ( Ke et al, 2020 ). Due to the late diagnosis and lack of long-term effective treatments, the 5-years survival rate of ovarian cancer is only 47.8% ( Zhang et al, 2016 ; Block et al, 2020 ).…”
Section: Introductionmentioning
confidence: 99%
“…According to the statistics of the American Cancer Society in 2020, over 21,000 women were diagnosed with ovarian cancer, of which nearly 14,000 women died from this disease ( Siegel et al, 2020 ). Despite the application of two newly developed molecularly targeted drugs, PARP inhibitors (PARPi) and antiangiogenic agents, ovarian cancer remains the most lethal gynecologic malignancy ( Ke et al, 2020 ). Due to the late diagnosis and lack of long-term effective treatments, the 5-years survival rate of ovarian cancer is only 47.8% ( Zhang et al, 2016 ; Block et al, 2020 ).…”
Section: Introductionmentioning
confidence: 99%
“…In nasopharyngeal carcinoma, ITGA3 was shown to simultaneously regulate the migration of tumor cells and angiogenesis within the tumor microenvironment (12). In ovarian cancer, the monoclonal antibody OV-Ab 30 − 7, which speci cally neutralizes ITGA3, restrained tumor progression and lengthened the survival of tumor-bearing mice, indicating that ITGA3 might be a potential therapeutic target for ovarian cancer (13). Although accumulating studies have begun to focus on the role of ITGA3 in tumors, its speci c role and underlying mechanisms are still unclear.…”
Section: Introductionmentioning
confidence: 99%